Floatz logo

Pexastimogene Devacirepvec

Colorectal Neoplasms

National Cancer Institute (NCI)gene_therapyPhase 1/2Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
73/ 100

Competitive context

118 Active assets in the Colorectal Neoplasms cohort.

Asset / SponsorPhaseRating
Eloxatin
Peking University Cancer Hospital & Institute
Phase 4BBB
Capecitabine
Rutgers, The State University of New Jersey
Phase 4BBB
FLUOROURACILUM
Rutgers, The State University of New Jersey
Phase 4BBB
Irinotecan
Shanghai Zhongshan Hospital
Phase 4BBB
Ferric Carboxymaltose [Ferinject]
Nottingham University Hospitals NHS Trust
Phase 4BBB

View all 50 →

Same molecule, other indications

Pexastimogene Devacirepvec is also rated in:

hepatocellular carcinomaDormant
BB
Indicative ·
65 / 100
View asset →
colorectal carcinomaDormant
B
Indicative ·
62 / 100
View asset →
hepatocellular carcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →